New hope for transplant patients: experimental drug aims to replace standard Anti-Rejection medication
NCT ID NCT07290777
Summary
This study is testing a new drug called VEL-101 to see if it can safely prevent the body from rejecting a new kidney after transplant. It will compare VEL-101 to the current standard medication, tacrolimus, in 120 people receiving a kidney transplant. Researchers want to see if VEL-101 works as well or better while potentially having fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANTATION, KIDNEY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.